TORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced changes to its board of directors (the “Board”). Effective today, Mr. Eyal Gabbai has been appointed to the Board replacing Dr. Gadi Riesenfeld, who has resigned from the Board. Dr. Riesenfeld will continue to support NurExone as a member of the Company’s Scientific Advisory Board.
The Company believes Mr. Gabbai’s experience in healthcare leadership, capital markets, and with global investors will be valuable as NurExone advances its preclinical programs toward first-in-human milestones and evaluates potential future capital markets opportunities, subject to market conditions and regulatory requirements.
“This appointment reflects our focus on engaging with partners who understand both patient needs and the economics of healthcare,” said Yoram Drucker, Chairman of NurExone. “Eyal brings deep experience across healthcare systems, technology adoption, market implementation, as well as a strong understanding of public company and regulated environments. His perspective will be valuable as we continue to build NurExone’s platform and engage with global partners, public-market stakeholders, and investors.”